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Abstract 
Background:  
All trials conducted to date on BRAVE-ONLINE for youth anxiety disorders have excluded 
children with High Functioning Autism Spectrum Disorder (HFASD) and therefore it is 
unknown whether these programs might be beneficial to HFASD children. The aim of this 
study was to evaluate the efficacy of BRAVE-ONLINE in HFASD children with an anxiety 
disorder.  
Methods: Forty-two HFASD children, aged 8 to 12 years, with an anxiety disorder, and their 
parents, were randomly assigned to either the BRAVE-ONLINE condition (NET) or a waitlist 
control (WLC). Diagnostic interviews and parent/child questionnaires were completed at pre-
treatment, post-treatment and 3-month follow-up.  
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Results: At post- assessment, compared to children in the WLC condition, children in the 
NET condition demonstrated a significantly greater reduction in number of anxiety diagnoses, 
clinical severity of diagnosis, and self and parent reported anxiety symptoms, as well as 
significantly greater increases in overall functioning. However, loss of primary diagnosis in 
this sample was lower than in previous studies.  
Limitations: The small sample size, coupled with attrition rates, makes it difficult to 
generalise the findings of the study to HFASD population and to conduct analyses regarding 
mediators, moderators and predictors of outcomes.  
Conclusions: The BRAVE-ONLINE program may be useful in reducing anxiety symptoms 
in HFASD children, although the effects are less strong than those found in neurotypical 
children for a variety of reasons.  
KEYWORDS:  
Autism Spectrum Disorder, HFASD, child anxiety, cognitive-behavior therapy, computer, 
Internet. 
Introduction 
High Functioning Autism Spectrum Disorder (HFASD) is a neuro-developmental 
condition characterised by impairment in social and communication skills, restricted and 
repetitive patterns of behaviours, motor difficulties and sensory hypersensitivities in the 
context of normative intelligence (APA, 2013; Green et al., 2012; Sudholsky et al., 2008). 
Comorbid childhood anxiety in children with Autism Spectrum Disorder (ASD) is as high as 
80% (Sukhodolosky, Bloch, Panza and Reichow, 2013), with 40% of children meeting 
criteria for an anxiety disorder (van Steensel et al., 2011). Understandably, comorbid anxiety 
can have a deleterious impact on the lives of children living with HFASD and their families, 
as it not only fosters its own negative consequences, it exacerbates core deficits of the 
disorder (Ghaziuddin, 2005; Sukholdolsky et al., 2008).  
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Research examining the use of cognitive behaviour therapy (CBT) for treating anxiety 
in children with HFASD has modified traditional CBT to better accommodate the unique 
profile of children with the disorder, and has now reached “probably efficacious” status 
according to the Chambless and Hollon (1998) criteria for empirically-validated treatments 
(Rudy et al., 2013). Common modifications involve increasing affective education, taking a 
more behavioural focus, targeting co-occurring ASD difficulties, increasing parental 
involvement and visual cues, and incorporating special interests (Attwood, 2008; Green & 
Wood, 2013).  
Sofronoff, Attwood and Hinton (2005) were among the first to modify CBT for 
children with HFASD and anxiety, finding that children in both the child only, and the parent 
involved conditions demonstrated significantly greater reductions in parent-reported levels of 
child anxiety compared to the WLC condition at 3-month follow up (Sofronoff, Attwood, & 
Hinton, 2005). Since that time, there have been a number of studies investigating the efficacy 
of modified CBT treatment protocols for anxiety with positive results (see Chalfant, Rapee, & 
Carrol, 2007; Fuji et al., 2013; Lang, Regester, Lauderdale, Ashbaugh and Haring, 2010; 
McNally Keehn, Lincoln, Brown, & Chivara, 2013; Reaven, Blakeley-Smith, Culhane-
Shelburne, & Hepburn, 2012; Reaven et al., 2009; Scarpa & Reyes, 2011; Sukhodolosky et 
al., 2013; Sung et al., 2011; Storch et al., 2013, 2015; Wood & Drahota, 2005; Wood et al., 
2009, 2015). Furthermore, in a recent systematic meta-analytic review of modified CBT for 
the treatment of anxiety in children with HFASD, it was found that modified CBT was 
superior to control conditions with a moderate effect size, and upon removal of child reported 
outcomes, the effect size increased (Ung, Selles, Small and Storch, 2015).  
Although it is clear that modified CBT works for anxious HFASD children, we do not 
know whether unmodified CBT programs for anxiety disorders might also be efficacious for 
this population. In the myriad of trials conducted on CBT for youth anxiety, HFASD children 
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have been routinely excluded, and therefore it remains unknown whether or not such 
programs would actually be helpful for these children. Indeed, it has been largely assumed 
that modifications are required for CBT anxiety programs to be efficacious, yet this has not 
actually been shown to be the case empirically to our knowledge. It is important to ascertain 
whether unmodified CBT programs might actually assist HFASD children with anxiety, as 
there are significantly more unmodified programs available to families, some of which are 
freely available. In contrast, modified CBT programs are less prolific and require specialist 
knowledge and training to deliver. If unmodified CBT programs are found to be efficacious 
for even a sub-group of HFASD children, it may reduce the significant burden on specialist 
agencies and allow families to more quickly, easily and affordably receive the help they 
require. Of particular usefulness in terms of availability, cost and convenience, is the potential 
for computer-based CBT programs for anxiety to be trialled with HFASD children. 
Computer-based CBT programs were developed in an attempt to reach the significant 
number of youth who either do not seek, or seek but do not receive, appropriate health 
services. It is thought that up to 80% of youth with anxiety disorders do not access or utilise 
the available health services (Booth et al., 2004; Boyd et al., 2007; Essau, 2005; Merikangas 
et al., 2011; Owens et al., 2002). A number of barriers to mental health help-seeking have 
been put forward including; stigma, poor mental health literacy, uncertainty regarding where 
to access support, unable to afford support costs, believing the problem would rectify itself, 
wanting to work the problem on their own or with help from family or friends, being a single 
parent, unemployed, and residing in a rural area (Booth et al., 2004; Lawrence et al., 2015; 
Lin, Goering, Offord, Campbell, & Boyle, 1996; Merikangas et al., 2011; Parikh, Wasylenki, 
Goering, & Wong, 1996; Wang et al., 2005). Computer-based approaches circumvent many 
of these barriers as they can be accessed anytime, within any setting (e.g. home, work, school) 
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and offer a sense of privacy and confidentiality (James et al, 2007, 2013; Richardson, Stallard, 
& Velleman, 2010).  
In addition to the advantages of computer-based CBT approaches discussed above, 
there are other reasons why computer-based CBT might be particularly useful and appealing 
to HFSAD youth. It is widely acknowledged that children with HFASD have specific 
interests, a frequent one of which is technology (Attwood, 2004, 2008).  Thus, computerised 
CBT treatments may arguably increase the likelihood for success through desire for 
engagement, enjoyment and subsequent reduction in affective dysregulation. Furthermore, 
online CBT programs are highly visual, animated, entertaining, and structured, attributes that 
ASD experts recommend for programs of any kind targeting ASD children (Attwood, 2004; 
Donoghue, Stallard, & Kucia, 2011; Odom et al., 2003; Sofronoff et al., 2005). Additionally, 
as HFASD families have numerous competing demands, offering a program that is flexible 
and able to be undertaken within the family home and schedule, may remove the associated 
stress and difficulties that go along with attending a clinic.  
For all of the above reasons, this study aimed to evaluate the efficacy of an 
unmodified, online CBT program for anxiety disorders (BRAVE-ONLINE) in a sample of 
HFASD children. Spence and colleagues (March et al, 2009; Spence, Holmes, March & Lipp, 
2006; Spence et al., 2011) have systematically evaluated BRAVE-ONLINE in a series of 
randomised controlled trials (RCTs). In their initial RCT, Spence, Holmes, March and Lipp 
(2006) compared the BRAVE program delivered partially via the Internet (CLIN-NET), with 
clinic based delivery (CLINIC) and a WLC group for children aged 7-14 years with a 
diagnosis of anxiety. The CLINIC group and CLIN-NET groups both demonstrated 
significantly greater reductions in anxiety from pre-to-post treatment compared to the WLC, 
with minimal differences between the two treatments in terms of efficacy. In the second RCT, 
March, Spence and Donovan (2009) examined the efficacy of a fully online version of 
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BRAVE (NET) for children aged 7-12 years compared to a WLC. At 6-month follow-up, 
75% of children in the NET group no longer met criteria for their primary anxiety diagnosis, 
and 60.7% were free of all anxiety diagnoses. The final RCT trialled an adolescent version of 
BRAVE-ONLINE (NET) compared to clinic delivery (CLIN) and a WLC, in a sample of 115 
adolescents aged 12 to 18 years with an anxiety diagnosis (Spence et al., 2011). By 12-month 
follow-up, 78.4% of the NET group and 80.6% of the CLIN group were free of their primary 
anxiety diagnosis, with minimal differences between the online and clinic versions conditions 
in terms of efficacy.  
 As noted above, unmodified CBT anxiety programs, whether they be face-to-face or 
computer-based, have not been tested in terms of their efficacy with HFSAD children. This 
study sought to examine the efficacy of the BRAVE-ONLINE program for HFASD children 
aged 8 to 12 years with an anxiety disorder. It was hypothesised that from pre to post-
treatment, NET children would demonstrate: greater remission; greater reduction in number 
of anxiety diagnoses, anxiety severity, anxiety symptoms, internalising behaviours; and a 
greater improvement in overall level of functioning, compared to WLC children. It was 
further hypothesised that these improvements would be maintained at 3-month follow-up. 
Method 
Participants 
 Forty-two Australian children aged between eight and twelve years (M=9.74; SD = 
1.3) with HFASD (AS) and one of their parents (97.6% mothers, 2.4% fathers) participated in 
the study. Table 1 outlines the socio-demographic information for the treatment group, the 
waitlist control group, and the total sample. As is evident from Table 1, 36 (85.7%) of the 
participants were male and 6 (14.3%) were female, with the majority being born in Australia. 
The majority of children (81%) resided with both biological parents, and had one or more 
siblings (97.6%). None of the families identified as being of Aboriginal and/or Torres Strait 
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Islander descent and the majority were of middle to high socio-economic status. Of the 
sample, 29 (69%) children had a primary diagnosis of Social Anxiety Disorder (SAnD), 12 
(28.6%) had Generalised Anxiety Disorder (GAD) and 1 (2.4%) had Specific Phobia (SP). 
The average number of anxiety diagnoses was 3.36 across the total sample, and all children 
met criteria for more than one anxiety disorder diagnosis. Table 2 outlines the comorbidity of 
the sample as a whole.     
Children were recruited Australia-wide through referrals from general practitioners, 
mental health professionals, school guidance officers, teachers, parents and media publicity. 
Self-referrals were also accepted. Figure 1 outlines the flow of participants through the study. 
As is evident from Figure 1, 21 participants were allocated to the NET condition and 21 were 
allocated to the WLC condition. For inclusion in the study, children were required to hold a 
diagnosis of Asperger’s Syndrome (AS) made by a health professional (paediatrician, 
psychologist, psychiatrist), with diagnoses confirmed by the Childhood Asperger Syndrome 
Test (CAST; Scott, Baron-Cohen, Bolton & Brayne, 2002) (see below). In addition, children 
were required to have a clinical diagnosis of either Separation Anxiety Disorder (SAD), SP, 
SAnD or GAD with a clinical severity rating (CSR) of 4 or greater according to the Anxiety 
Disorders Interview Scale for Children (ADIS-C/P; Silverman & Albano, 1996). To be 
eligible for study inclusion, children also had to be aged between 8 to 12 years, able to read 
and write English at a minimum age 8 years level, and have access to a computer equipped 
with internet access from home. A minimum diagnostic severity rating of 4, based on an 8-
point clinician scale, was required, and comorbidity with other anxiety disorders and 
externalising disorders was permissible. Children, who were identified as meeting clinical 
levels of depression, dysthymia or an externalising disorder above a CSR of 5 as measured by 
the ADIS-C/P were not included in the study for ethical reasons and were referred elsewhere 
for appropriate support. Children were also excluded if they were receiving psychosocial 
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treatment for anxiety elsewhere, had a diagnosed learning disorder, or possessed significant 
intellectual or physical impairment.  
Measures 
For the NET group, all measures outlined below were taken at pre, post and 3-month 
follow-up, with the exception of the CAST (Scott, Baron-Cohen, Bolton & Brayne, 2002) and 
the demographic questionnaire that were only administered at pre-treatment (see below). The 
WLC group completed questionnaires at pre and post-treatment only.  
Demographics.  
Parents were required to report mother and fathers’ age, gender of parent completing 
questionnaires, combined family income, mother and father’s highest level of education, and 
marital status. Additionally, they were required to report information relating to their child’s, 
age, gender, country of birth, cultural identification, year level at school, number of siblings 
and living circumstances.   
Childhood Asperger Syndrome Test (CAST;  
Scott, Baron-Cohen, Bolton & Brayne, 2002). For all participants, the CAST was used 
to support the parent-reported professional diagnosis of Asperger’s Syndrome (AS). The 
CAST is a 37-item parent-report questionnaire designed to screen for high-functioning autism 
spectrum conditions in school-aged children. Thirty-one of the 37 items are summed to 
provide an overall score, with the remaining 6 items related to general development. A cut-off 
score of 15 or greater indicates the potential presence of AS. Using the cut-off score of 15, the 
CAST demonstrates a sensitivity of .88, a positive predictive value of .64 and a specificity 
value of .98 (Scott et al., 2002). It has been found to have a moderate to high test-retest 
reliability of .70 (kappa statistic).  
 Anxiety Disorders Interview Schedule for DSM-IV: Parent and Child Version.  
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Children’s diagnostic status was evaluated using a telephone administration of the Anxiety 
Disorders Interview Schedule for DSM-IV (ADIS–C/P; Silverman & Albano, 1996). The 
telephone version of the ADIS-C/P has been shown to be equivalent in terms of reliability and 
validity and was necessary given that participants were recruited Australia-wide (Cobham, 
Dadds & Spence, 1998, 2010; Lyneham & Rapee, 2005). The ADIS-C/P is a semi-structured 
interview that allows for the identification of current anxiety disorders.  Each diagnosis is 
given a clinician severity rating (CSR) that may range from 0 (no interference) to 8 (extreme 
or disabling interference), with scores of 4 (moderate interference) and above indicative of 
clinical impairment. As recommended by Silverman and Albano (1996), child and parent 
scores were combined to provide a composite diagnosis of the child’s reported difficulties. 
Interviewers were registered psychologists with a minimum of eight hours training in the 
schedule and who were blind to treatment condition. All interviewers received ongoing 
supervision by a psychologist throughout the study. The ADIS-C/P has displayed good to 
excellent test-retest reliability, with kappa’s rating from .61 to 1.00 and moderate to high 
inter-rater reliability, with kappa’s ranging from .45 to 1.00  (Lyneham & Rapee, 2005; 
Rapee, Barrett, Dadds, & Evans, 1994; Silverman & Eisen, 1992; Silverman, Saavedra, & 
Pina, 2001).  
 The Children’s Global Assessment Scale. 
 The Children’s Global Assessment Scale (CGAS; Schaffer et al, 1983) was used to measure 
the child’s overall level of functioning, with clinicians assigning a rating based on 
information gathered from the ADIS-C/P. The child is assigned a score ranging from 0 to 100, 
with higher scores indicating a higher level of functioning. Scores of 0-40 represent serious 
disability or impairment, scores of 41-60 indicate moderate disability or impairment, scores of 
61-80 suggest slight disability or impairment, and scores of 81-100 indicate a normal level of 
functioning (Schaffer et al., 1983). The CGAS has demonstrated good inter-rater reliability (r 
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= .84) and test–retest reliability (r = .85; Dyrborg et al., 2000; Rey, Starling, Wever, Dossetor, 
& Plapp, 1995; Schaffer et al., 1983). 
 Child Behavior Checklist – Revised. 
 The Child Behavior Checklist – Revised (CBCL; Achenbach & Rescorla, 2001) was used to 
assess internalising behaviours.  Parents were required to rate the extent to which each item 
was representative or characteristic of their child on a 3-point scale (0 = “not true”; 1 = 
“somewhat or sometimes true”; and 2 = “very true or often true”). The internalising scale 
(CBCL-int) consists of 32 items that are scored to produce an internalising score that may 
range from 0 to 64, with higher scores indicating greater internalising behaviours. The CBCL 
has demonstrated excellent psychometric properties, with test-retest reliability found to range 
from .95 to 1.00 and internal consistency estimates ranging from .78 to .97 (Achenbach & 
Rescorla, 2001). The reliability of the CBCL-int subscale was .88 in the current study. 
 Spence Children’s Anxiety Scale – Child (SCAS-C; Spence, 1998) and Parent (SCAS-
P; Spence, 1999) Versions. The SCAS-P and SCAS-C were used to assess child anxiety 
symptoms. The SCAS-C consists of 44 items while the SCAS-P comprises 38 items that are 
summed to produce a total score that may range from 0 to 114, with higher scores indicating 
greater anxiety. Children and parents are required to indicate how often the child experiences 
each item on a 4-point scale from 0 (never) to 3 (always). The SCAS-C and SCAS-P have 
been found to have excellent internal consistencies of .92 and .89 respectively (Muris, 
Schmidt, & Merckelbach, 2000; Spence, 1998; Spence, Barrett, & Turner, 2003). The 
reliability of the SCAS-C was .86 and the SCAS-P was .88 in the current study. 
 Satisfaction with Treatment.  
Satisfaction with the program was measured with an 8-item rating scale designed by Spence, 
Holmes, March and Lipp (2006). The questionnaire was completed by NET children and 
parents at post-assessment and follow-up. Participants were requested to rate their satisfaction 
 11 
with the program on a 5-point scale from 1 (not at all true) to 5 (very true). Scores were 
averaged to provide a mean satisfaction score, with higher scores indicating higher levels of 
satisfaction (Spence et al., 2006).   
Procedure 
Following Griffith University ethics approval, participants were recruited Australia 
wide through referrals from general practitioners, mental health professionals, school 
guidance officers and media publicity. Self-referrals were also accepted. Upon registration of 
interest, referrals were screened by telephone using a standard screening interview and the 
CAST, in order to determine eligibility for the study. Pre-assessment occurred prior to 
random allocation to eliminate any potential bias. Once deemed potentially eligible, 
participants were directed to an online information and consent page, and following consent, 
then went on to complete the online questionnaire package. After questionnaire completion 
and subsequent screening of the questionnaires, children and parents deemed likely to hold a 
clinical-level anxiety disorder completed the ADIS-C/P. Children who were confirmed to 
have both AS and a clinical-level anxiety disorder were included. All families excluded from 
the study were provided with appropriate referrals.   
Eligible children were randomly allocated to condition (NET versus WLC) via a 
computer program that produced an order of inclusion in advance of the study that was 
unknown to the researcher assigning participants to condition.  Evaluation of the NET group 
participants was conducted at pre-treatment, post-assessment (approximately 10-14 weeks 
following the commencement of treatment) and 3 month follow-up while WLC participants 
were assessed at times corresponding to pre-treatment and post-assessment. Post-assessment 
and 3-month follow-up were conducted by independent interviewers who were blind to 
condition and assessment time-point. After completing their post-treatment evaluations, 
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children in the WLC group ceased to be part of the study and were provided access to the 
BRAVE-ONLINE program.  
Treatment Protocol / Intervention 
The BRAVE -ONLINE program was developed as a transdiagnostic CBT intervention 
for the treatment of SAD, SAnD, SP and GAD (March et al, 2009; Spence et al., 2006, 2011). 
For a comprehensive review of the program, see Spence et al.,  (2008). The program consists 
of 10 child, and six parent sessions, each 60-minutes in length, that are completed weekly 
online via the Internet, as well as two booster sessions undertaken one and three months after 
completion of the program. BRAVE-ONLINE is therapist assisted in that participants receive 
weekly, online contact with a therapist in response to session activities, as well one short 
phone call midway through the program to assist with exposure hierarchy construction. 
Data Analysis 
Preliminary analyses using a series of chi square, ANOVA and MANOVA were 
conducted on the entire sample (N=42) to ensure that there were no pre-existing differences 
between the treatment and waitlist conditions on any of the demographic or outcome variables 
prior to treatment. Linear mixed model analyses were conducted with the intent to treat (ITT) 
sample to determine the relative change in outcome variables over time between the NET and 
WLC groups.  
Results 
Pre-Treatment Comparisons 
With regard to demographic variables prior to treatment, chi-squared analyses 
revealed no significant differences between the groups on child gender χ2 (1, N = 42) = 3.11, 
p = .184, child country of birth χ2 (1, N = 42) = 1.11, p = .606,  combined family income χ2 (4, 
N = 42) = 4.58, p = .333, maternal level of education χ2 (5, N = 42) = 1.07, p = .957, or 
paternal level of education χ2 (6, N = 42) = 9.49, p = .148. Similarly, univariate analyses of 
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variance (ANOVAs) showed that there were no significant differences between conditions on 
child age F(1, 40) = .12,  p = .732, η2 = .003, mother age F(1, 40) = .81, p = .375, η2 = .02, or 
father age F(1, 39) = .01, p = .934, η2 < .001 prior to treatment.  
With respect to outcome variables, the MANOVA including number of diagnoses, 
CSR and CGAS at pre-treatment was not found to be significant, Pillai’s F(3, 38) = .094, p 
=.285, η2  = .094, thus suggesting no significant pre-existing differences between the NET and 
WLC conditions on these variables prior to treatment. Similarly, the MANOVA including 
pre-treatment SCAS-C, SCAS-P and CBCL-int was not found to be significant, Pillai’s F(3, 
38) = .05, p =.59, η2  = .049, suggesting no significant differences prior to treatment between 
the NET and WLC groups on these variables.  
Outcome measures at post-assessment and 3-month follow-up 
 The estimated marginal means for Number of Diagnoses, CSR, CGAS, SCAS-C, 
SCAS-P and CBCL-INT are presented in Table 3 (pre- to post-assessment for NET and WLC 
groups) and Table 5 (pre- to post-assessment and 3-month follow-up for the NET group).  
The fixed effects for intercept and slopes and effect sizes are presented in Table 4 (pre- to 
post-assessment for NET and WLC groups) and Table 6 (pre- to post-assessment and follow-
up for the NET group). 
For the completer sample, 20% of the NET group versus 0% of the WLC group were 
free of their primary diagnosis at post-assessment, with 38.9% of the NET group being free of 
their primary diagnosis by 3-month follow-up. With respect to loss of all anxiety diagnoses 
(for the completer sample), 10% of the NET group versus 0% of the WLC group had lost all 
anxiety diagnoses by post-assessment, with 16.7% of the NET group being free of all 
diagnoses by 3-month follow-up. There were no significant differences between the NET and 
WLC groups (completer sample) at post-assessment on those free of their primary diagnosis, 
χ2 (1, N=38) =4.02, p=.107 or those free of all diagnoses, χ2 (1, N=38) =1.90, p=.488. 
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For the ITT sample, 19% of the NET group versus 0% of the WLC group were free of 
their primary diagnosis at post-assessment, with 33.3% of the NET group being free of their 
primary diagnosis by 3-month follow-up. With respect to loss of all anxiety diagnoses (for the 
ITT sample), 9.5% of the NET group versus 0% of the WLC group had lost all anxiety 
diagnoses by post-assessment, with 14.3% of the NET group being free of all diagnoses by 3-
month follow-up. There were no significant differences between the NET and WLC groups 
(ITT sample) at post-assessment on those free of their primary diagnosis, χ2 (1, N=42) =4.42, 
p=.107 or those free of all diagnoses, χ2 (1, N=42) =2.10, p=.488. 
With respect to number of anxiety diagnoses, there was a significant effect for time, 
F(1, 39.95) = 5.42, p=.025, and a significant condition by time interaction, F(1, 39.95) = 
32.14, p<.001 from pre to post-treatment, as well as a significant effect for time from pre- to 
3-month follow-up, F(2, 36.38) =24.75, p<.001. In terms of CSR of the primary diagnosis, 
there was a significant effect for time, F(1, 42.16) = 26.71, p<.001, and a significant condition 
by time interaction, F(1, 42.16) = 12.57, p =.001 from pre to post assessment, together with a 
significant effect for time from pre to 3-month follow-up, F(2, 40.93) =16.09, p<.001. 
Similarly, with respect to the CGAS, there was a significant effect for time, F(1, 40.23) 
=44.11, p<.001, and a significant condition by time interaction, F(1, 40.23) = 18.56, p <.001 
from pre-assessment to post-assessment, as well as a significant effect for time from pre to 3-
month follow-up, F(2, 38.51) = 33.53, p <.001. The results for the SCAS-C and SCAS-P 
painted a similar picture. There was a significant effect for time, F(1, 32.49) =77.03, p<.001, 
and a significant condition by time interaction, F(1, 32.49) =4.83, p=.035 for the SCAS-C 
from pre to post-assessment as well as a significant effect for time from pre to 3-month 
follow-up, F(2, 28.46)=38.95, p<.001. Similarly, there was significant effect for time, F(1, 
36.25) =33.10, p<.001, and a significant condition by time interaction, F(1, 36.25) =4.49, 
p=.041 from pre to post-assessment for the SCAS-P as well as a significant effect for time 
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from pre to 3-month follow-up, F(2, 33.92)=18.99, p<.001. Finally, with respect to the 
CBCL-int, there was a significant effect for time, F(1, 36.10) =35.59, p<.001, and a 
significant condition by time interaction, F(1, 36.10) =7.18, p=.011 from pre-assessment to 
post-assessment, together with a significant effect for time from pre to 3-month follow-up, 
F(2, 33.88) =25.85, p<.001. Inspection of Tables 4, 5 and 6 indicate that the NET group 
showed a significantly greater reduction in number of anxiety diagnoses, CSR, CGAS, SCAS-
C, SCAS-P, and CBCL-int from pre to post treatment compared to the WLC group, with 
treatment effects being maintained at 3-month follow-up.  
Session Completion 
            At the post-assessment time point, parents in the NET group had completed a mean of 
4.86 (SD=1.85) out of six sessions, with 71.5% completing Session 5 (the exposure session) 
and 42.9% completing all six sessions. At the 3-month follow-up time point, parents had 
completed a mean of 5.24 (SD=2.21) out of six sessions. There were no differences in the 
number of completed sessions at post-assessment and follow-up, with 71.5% of parents 
completing Session 5 (the exposure session) and 42.9% all six sessions at 3-month follow-up.  
At the post-assessment time point, children in the NET group had completed a mean 
of 6.71 (SD=2.99) out of 10 sessions, with 81% completing Session 5 (the exposure session) 
and 19% completing all 10 sessions. At the 3-month follow-up time point, children had 
completed a mean of 7.38 (SD= 3.60) out of 10 sessions. At follow-up, again 81% of children 
had completed Session 5, and 38% had completed all 10 sessions.   
Treatment Satisfaction 
Satisfaction data were collected from 14 children and 18 parents of the NET group. 
Children and parents reported moderate levels of satisfaction following treatment (child 
ratings: M = 3.03, SD = 1.03; parent ratings: M = 3.58, SD = 0.86).  
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Discussion 
 The aim of this study was to evaluate the efficacy of an Internet-based cognitive-
behavioural therapy (CBT) intervention (BRAVE-ONLINE) for the treatment of child anxiety 
disorders in children with HFASD. Results indicated that there were no significant differences 
between the NET and WLC groups regarding loss of primary diagnosis at post-assessment. 
However, compared to children in the WLC group, children in the NET condition 
experienced significantly greater reductions in number of diagnoses, clinical severity of 
primary diagnosis, global assessment of functioning, anxiety symptoms and internalising 
behaviours, with treatment gains being maintained at 3-month follow-up.  
 Turning first to the results concerning the number of children free of their primary 
diagnosis. In the current study, 20% and 38.9% of NET children (in the completer sample) 
were free of their primary diagnosis at post-assessment and 3-month follow-up respectively. 
This can be compared to the March et al (2009) study that examined the same BRAVE-
ONLINE program with similarly aged neurotypical children, where 30% and 75% of children 
were free of their primary diagnosis at post-assessment and 6-month follow-up respectively. 
On a broader level, modified CBT programs have yielded remission rates ranging from no 
significant differences in loss of primary diagnosis (McConachie et al., 2014), to 71.4% 
(Chalfant et al., 2007; Fuji et al., 2013) at post-treatment. Thus, it is clear that the results are 
substantially less impressive for the present study, with a number of possible explanations for 
why this might be so. 
  One explanation concerns treatment compliance and the length of time taken to 
complete treatment. In the current study, 19% and 38% of children had completed all 10 
sessions at post-assessment and 3-month follow-up respectively, compared to 33.3% and 62% 
in the March et al (2009) study. Similarly, 42.9% of parents had completed all 6 sessions at 
post-assessment and 3-month follow-up, compared to 60% and 72.3% in the March et al 
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(2009) study.  Thus, HFASD families appeared to complete fewer sessions that than their 
neurotypical counterparts and therefore it is perhaps not surprising that their remission rates 
were lower. The substantially lower compliance rates in the current study may be due to the 
myriad of difficulties faced by families with a HFASD child. It is likely that the intensified 
strain experienced by these families, places greater stress on the individual and the family 
system, perhaps making it more difficult to comply with a largely self-help program, and to 
apply and generalise the strategies learned. 
A second reason for the lower remission rates in the present study may be due the 
difference in follow-up time points between March et al (2009) and the current study, with the 
March et al (2009) study employing a 6-month follow-up and the present study employing on 
a 3-month follow-up. Our 3-month follow-up point may not have been long enough for 
treatment effects to become evident. In contrast, a 6- or 12-month follow-up point would 
allow sufficient time for skill application and generalisation, and potentially the subsequent 
loss of primary diagnosis.  
Despite the rather lack lustre results for loss of diagnosis, there were significantly 
greater reductions for the NET group compared to the WLC group on all other measures over 
time, suggesting that the program was effective in reducing anxiety and improving overall 
level of functioning. These findings are consistent with those of the March et al (2009) study, 
where at post-assessment, children in the NET group showed significantly greater 
improvement in clinical severity of primary diagnosis, global assessment of functioning, 
parent-reported levels of anxiety and internalising behaviours compared to the WLC. 
Similarly, with respect to satisfaction, both children and parents reported moderate levels of 
satisfaction, consistent with those reported in the March et al (2009) study of neurotypical 
children. Thus, it would seem that significant improvement in anxiety and general functioning 
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occurred as the result of treatment, despite remission rates being lower, and that both parents 
and children were largely satisfied with the program.  
Strengths, Limitations and Future Research Directions 
Despite the strengths of this study, there were also a number of limitations. First, 
although the CAST was included as a check to ensure the integrity of the HFASD diagnosis 
given by a paediatrician, it is not considered the gold standard in HFASD diagnosis. Future 
research should ensure that the ADOS-2 (Lord et al., 2012), frequently considered the gold 
standard in ASD diagnosis, is used to determine diagnostic status.  Additionally, inter-rater 
reliability of the ADIS-C and ADIS-P were not assessed and is noted as a limitation of the 
study that should be addressed in future research. Furthermore, the study was pilot in nature 
and therefore had a somewhat small sample size. Increasing the sample size would enable 
investigation of predictors, mediators and moderators of treatment outcome, which would 
allow determination of which particular HFASD children might benefit from unmodified 
online CBT for anxiety and the mechanisms through which this might occur. Potential 
predictors / moderators of treatment outcome might include presence of another child with 
ASD or psychopathology, parental and family stress, age of child, and number of children in 
the family. Future research should employ larger sample sizes so that potential predictors and 
mechanisms of change can be investigated. 
Another limitation involves the substantial attrition across the course of the study and 
the less-than-perfect session completion rates evident, both of which bring up a number of 
issues. First, the fact that some children were lost to follow-up and others failed to complete 
all sessions, is likely to be at least in part due to the fact that families with a HFASD child 
have many competing demands and as a result can be quite chaotic. These issues can be 
problematic for face-to-face treatment as well, but are likely to be even more problematic 
when therapy is conducted online where it is easier to ‘put off’ sessions more easily. 
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Interestingly, the number of sessions completed was not markedly different from that found 
by March et al (2009), with both child and parent participants in the present study completing 
approximately one less session each than the neurotypical children in the March et al (2009) 
study at post-assessment. Indeed, non-completion of sessions is problematic for internet-
programs and has been noted in all studies conducted on BRAVE-ONLINE to date (March et 
al., 2009; Spence et al., 2008; Spence et al., 2011). Sessions are designed to be interesting and 
stimulating for children and parents. However, unassisted completion of sessions still requires 
significant motivation and organisation. Thus, for both neurotypical and HFASD children, it 
is important for future research to determine family and child characteristics that predict both 
session completion and treatment outcome. Equally, research investigating not only session 
compliance but also compliance with homework (and particularly exposure) exercises in 
relation to treatment outcome will also be important for both neurotypical and HFSAD 
children engaged in online therapy for anxiety. It may be that it is not so much the number of 
session completed that is important to treatment outcome, but rather the homework (and 
particularly exposure homework) that is completed. Future research should investigate the 
potential roles of session completion and homework completion on treatment outcome.  
Another limitation to the study is the absence of a face-to-face CBT comparison 
group, making it difficult to conclude whether it was the unmodified nature of the program, or 
the online delivery of the program that resulted in the effects found. Future research should 
include a face-to-face condition to allow for this comparison. Furthermore, although this 
study was an important first step in testing the usefulness of unmodified, online CBT for 
anxiety in children with HFASD, it will be important for future research to extend upon this 
study by determining the relative efficacy of modified versus unmodified online, CBT for 
anxiety in children with HFASD.  
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 Finally, the absence of a control group at 3-month follow-up, made it impossible to 
determine whether improvements evident at the 3-month assessment point were the result of 
natural recovery or the effects of treatment and highlight another limitation. It is suggested 
that future research extends the wait-list period past the post-treatment point and onto follow-
up periods to allow better determination of whether further improvements are being made due 
to treatment or whether they are simply due to the passage of time.  Furthermore, the 3-month 
follow-up point may not have been long enough to determine possible positive effects of the 
program. Thus, future research should include employ 6- and 12-month follow-up points to 
better assess the long-term usefulness of the program.  
Conclusions and Clinical Implications 
 Given the significant rates of anxiety disorder in children with HFASD and the 
deleterious impact on both the individual and their families, it is essential to explore the 
efficacy of readily available standardised CBT interventions for this population. The results of 
this small, pilot RCT provide preliminary evidence that unmodified standardised CBT 
programs for the treatment of anxiety disorders in children can produce statistically 
significant reductions in anxiety for HFASD children with anxiety. Although these results 
require replication, they suggest promise in broadening available, cost effective and easily 
accessible standardised CBT intervention options for the successful treatment of anxiety in 
individuals with HFASD and their families.  
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Figure 1. CONSORT Diagram 
 
Table 1 Pre-treatment Socio-demographic Information (N=42)  
Demographic Treatment  
(n = 21) 
Waitlist 
 (n = 21) 
Total  
(N = 42) 
Gender (%) 
Female 
Male 
 
23.8 
76.2 
 
4.8 
95.2 
 
14.3 
85.7 
 
Age in years (Mean) 
Child 
Mother 
Father 
 
9.81 
40.86 
42.24 
 
 
9.67 
39.62 
42.40 
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40.24 
42.32 
 
Random allocation (N =  42) 
Post-assessment  
 
18 completed ADIS 
Parent – 18 completed questionnaires 
Child – 18 completed questionnaires 
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Child – 15 completed questionnaires 
 
Received treatment 
 
No further assessment 
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Combined family income (%) 
<AU $40,000 
AU $41,000- AU $60,000 
AU $61,000- AU $80,000 
AU $81,000- AU $100,000 
>AU$100,000 
 
 
9.5 
14.3 
19.0 
4.8 
52.4 
 
 
4.8 
9.5 
19.0 
28.6 
38.1 
 
 
7.1 
11.9 
19.0 
16.7 
45.2 
Highest level of education (%) 
Mother 
Postgraduate University Degree 
Undergraduate University Degree 
TAFE or Apprenticeship 
Completed Year 12 
Completed Year 10 
 
 
 
28.6 
9.5 
42.9 
9.5 
9.5 
 
 
19.0 
9.5 
42.9 
19.0 
9.5 
 
 
23.8 
9.5 
42.9 
14.3 
9.5 
 
Highest level of education (%) 
Father 
Postgraduate University Degree 
Undergraduate University Degree 
TAFE or Apprenticeship 
Completed Year 12 
Completed Year 10 
Did Not Complete Year 10 
 
 
 
19 
23.8 
42.9 
0 
9.5 
4.8 
 
 
9.5 
33.3 
42.8 
14.3 
0 
0 
 
 
14.3 
28.6 
42.9 
7.1 
4.8 
2.4 
Child’s country of birth (%) 
Australia  
United Kingdom 
Scotland 
United States of America 
 
 
85.7 
9.6 
0 
4.8 
 
95.2 
0 
4.8 
0 
 
90.5 
4.8 
2.4 
2.4 
 
 
Table 2 Pre-treatment Diagnostic Information for total sample according to condition 
             Treatment  
           N=21 
            Waitlist 
              N=21 
 
Mean severity of primary anxiety     
     diagnosis 
Mean number of anxiety disorders  
CGAS rating  
 
  
6.62 
 
3.38 
48.52 
 
             6.76 
 
             3.33 
             46.05 
 
 
 
 
 
 
Primary Anxiety Diagnosis 
 
N 
 
 
% of 
children  
 
 
N 
 
 
15 
% of 
children  
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     Social Anxiety Disorder 
     Generalised Anxiety Disorder  
     Specific Phobia - Dark 
      
Secondary Anxiety Diagnosis  
     Social Anxiety Disorder  
     Generalised Anxiety Disorder 
     Separation Anxiety Disorder  
     Specific Phobia – Blood 
     Specific Phobia – Dark 
     Specific Phobia – Insects 
     Specific Phobia - Thunderstorms 
14 
7 
0 
 
 
6 
12 
1 
1 
1 
0 
0 
 
 
66.7 
33.3 
0 
 
 
28.6 
57.1 
4.8 
4.8 
4.8 
0 
0 
 
 
5 
1 
 
 
          4 
          11 
          2 
          0   
          2 
          1 
1 
 
 
71.4 
23.8 
4.8 
 
 
19.0 
52.4 
9.5 
0 
9.5 
4.8 
4.8 
 
 
Note: Severity = 0 (none) to 8 (severe), CGAS = Children’s Global Assessment Scale 
 
Table 3 Estimated marginal means and standard errors for Outcome Variables from pre- to 
post-assessment 
  NET WLC 
 Time M SE d M SE d 
Number of 
Diagnoses 
 
Pre 
 
3.38 
 
.26 
  
3.33 
 
.26 
 
 Post 1.79 .26 .95 4.00 .27 -.39  
CSR Pre 6.62 .31  6.76 .31  
 Post 4.10 .31 1.25 6.29 .33 .23 
CGAS 
 
SCAS-C 
Pre 
Post 
Pre 
48.52 
62.10 
39.10 
1.65 
1.68 
2.98 
 
-1.26 
46.05 
48.94 
38.48 
1.65 
1.75 
2.98 
 
-.26 
 Post 23.77 3.20 .77 29.29 3.06 .47 
SCAS-P Pre 36.95 3.21  36.62 3.21  
 Post 23.80 3.32 .62 30.55 3.32 .29 
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CBCL-INT Pre 22.62 2.19  25.91 2.19  
 Post 12.91 2.27 .67 22.22 2.27 .26 
Note: Effect sizes were calculated from Pre to Post within condition. 
 
Table 4 Effects for NET and WLC for Outcome Variables from pre- to post-assessment  
 B SE ES 
Number of Diagnoses 
     Intercept 
 
 
  
          WLC baseline 3.38*** .26 4.06 
          NET-WLC -.05 .35  -.06 
     Slope pre to post    
          WLC slope -1.60*** .28 -1.92 
          NET-WLC slope 2.26*** .40  2.72 
     Random Effects    
          Level 1 residual variance   .73  
          Level 2 residual variance  -.04  
 
CSR 
     Intercept 
 
 
  
          WLC baseline 6.62*** .31 6.23 
          NET-WLC .14 .43   .14 
     Slope pre to post    
          WLC slope -2.52*** .40 -2.37 
          NET-WLC slope 2.05*** .58  1.93 
     Random Effects    
          Level 1 residual variance  1.39  
          Level 2 residual variance  -.26  
 
CGAS 
     Intercept 
 
 
  
          WLC baseline 48.52*** 1.65 9.08 
          NET-WLC -2.48 2.33 -.46 
     Slope pre to post    
          WLC slope 13.58*** 1.72  2.54 
          NET-WLC slope -10.69*** 2.48 -2.00 
     Random Effects    
          Level 1 residual variance  29.24  
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          Level 2 residual variance  -.66  
* p<.05; **p<.01; ***p<.001                   (continued) 
Note: Effect sizes were calculated as estimated fixed effects divided by the square root of the 
sum of the two variance components 
 
 B SE ES 
    
SCAS - C 
     Intercept 
   
          WLC baseline 39.10***  2.98  4.54 
          NET-WLC -.62  4.22   -.07 
     Slope pre to post    
          WLC slope -15.33***  2.09 -1.78 
          NET-WLC slope 6.14*  2.79    .71 
     Random Effects    
          Level 1 residual variance  52.79  
          Level 2 residual variance  21.41  
 
SCAS - P 
     Intercept 
   
          WLC baseline 39.95***  3.21  4.10 
          NET-WLC -.33  4.54   -.03 
     Slope pre to post    
          WLC slope -13.15***  2.36 -1.35 
          NET-WLC slope 7.08*  3.34    .73 
     Random Effects    
          Level 1 residual variance  73.08  
          Level 2 residual variance  21.96  
 
    
CBCL - INT 
     Intercept 
   
          WLC baseline 22.62***  2.19 3.41 
          NET-WLC 3.29  3.10  .50 
     Slope pre to post    
          WLC slope -9.71***  1.59 -1.47 
          NET-WLC slope 6.02*  2.25    .91 
     Random Effects    
          Level 1 residual variance  33.48  
          Level 2 residual variance  10.42  
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* p<.05; **p<.01; ***p<.001                   (continued) 
Note: Effect sizes were calculated as estimated fixed effects divided by the square root of the 
sum of the two variance components. 
 
Table 5 Estimated marginal means and standard errors for Outcome Variables from pre- to 
post-assessment and 3-month follow-up 
 NET 
 Time M SE d 
Number of Diagnoses Pre 3.38 .21  
 Post 1.77 .22  
 
3-mth 1.46 .23 1.91 
CSR Pre 6.62 .45  
 Post 4.11 .46  
 
3-mth 3.37 .48 1.54 
CGAS 
 
 
 
SCAS-C 
Pre 
Post 
3-mth 
 
Pre 
48.52 
62.10 
67.12 
 
39.10 
1.89 
1.92 
2.01 
 
2.78 
 
 
-2.08 
 Post 23.40 2.94  
 
3-mth 22.10 3.01 1.28 
SCAS-P Pre 36.95 3.29  
 Post 23.89 3.39  
 
3-mth 21.07 3.49 1.03 
CBCL-INT Pre 22.62 2.07  
 Post 12.95 2.13  
 
3-mth 11.86 2.20 1.10 
Note: Effect sizes were calculated from Pre to 3-month within condition. 
 
Table 6 Effects for NET Outcome Variables from pre- to post-assessment and 3-month follow-
up  
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 B SE ES 
 
Number of Diagnoses 
     Slope pre to post 
   
          NET pre to 3-month -1.92*** .31 -2.53 
          NET pre to post -1.62*** .27 -2.13 
     Random Effects    
          Level 1 residual variance  .04  
          Level 2 residual variance  .94  
CSR 
     Slope pre to post 
   
          NET pre to 3-month -3.25*** .62 -1.52 
          NET pre to post -2.51*** .53 -1.18 
     Random Effects    
          Level 1 residual variance  .40  
          Level 2 residual variance  4.17  
CGAS 
     Slope pre to post 
          NET pre to 3-month 
          NET pre to post 
 
     Random Effects 
          Level 1 residual variance 
          Level 2 residual variance  
 
SCAS-C 
     Slope pre to post 
 
 
18.59*** 
13.58*** 
 
 
2.45 
1.96 
 
 
17.09 
74.74 
 
 
1.94 
1.42 
          NET pre to 3-month -17.00*** 2.43 -1.02 
          NET pre to post -15.70*** 1.84 -0.95 
     Random Effects    
          Level 1 residual variance  114.15  
          Level 2 residual variance  162.34  
* p<.05; **p<.01; ***p<.001                 (Continued) 
Note: Effect sizes were calculated as estimated fixed effects divided by the square root of the 
sum of the two variance components. 
 
 B SE ES 
 
SCAS-P 
     Slope pre to post 
   
          NET pre to 3-month -15.88*** 3.02 -0.82 
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          NET pre to post -13.07*** 2.23 -0.68 
     Random Effects    
          Level 1 residual variance  145.62  
          Level 2 residual variance  227.14  
CBCL-INT 
     Slope pre to post 
   
          NET pre to 3-month -10.76*** 1.87 -0.88 
          NET pre to post   -9.67*** 1.38 -0.79 
     Random Effects    
          Level 1 residual variance  58.76  
          Level 2 residual variance  90.02  
* p<.05; **p<.01; ***p<.001 
Note: Effect sizes were calculated as estimated fixed effects divided by the square root of the 
sum of the two variance components. 
 
 
 
Highlights 
 Anxiety is often comorbid with high functioning autism spectrum disorder (HFASD)  
 Prior research has trialled modified CBT programs for anxiety in HFASD children 
 This study investigates unmodified internet-based CBT for anxiety in HFASD children 
 Significant reductions in anxiety and internalising symptoms were demonstrated 
 Significant increases in global functioning were also shown 
 
